X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761024
https://www.prnewswire.com/news-releases/celltrion-usa-announces-incorporation-of-adalimumab-aaty-a-humira-biosimilar-to-the-costco-member-prescription-program-302220446.html
https://www.globenewswire.com/news-release/2024/07/31/2921750/0/en/Teva-Announces-Strong-Growth-in-Second-Quarter-Revenues-mainly-driven-by-Generics-Products-in-All-Regions-and-AUSTEDO-Raises-2024-Financial-Guidance.html
https://www.globenewswire.com/news-release/2024/07/11/2911765/0/en/Samsung-Bioepis-Releases-Third-Quarter-2024-US-Biosimilar-Market-Report.html
https://www.globenewswire.com/news-release/2024/06/27/2905181/33333/en/Coherus-BioSciences-Announces-Divestiture-of-YUSIMRY-adalimumab-aqvh-in-a-40-Million-Upfront-All-Cash-Transaction.html
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-inks-immune-disorder-drug-licensing-deal-with-chinas-futuregen-2024-06-13/
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-tight-grip-humira-market-raises-concerns-about-biosimilars-2024-06-07/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761255
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761255
https://endpts.com/senators-strike-bipartisan-tone-on-more-pharma-patent-reforms/
https://www.globenewswire.com/news-release/2024/05/21/2885215/0/en/Teva-and-Alvotech-Announce-SIMLANDI-adalimumab-ryvk-Injection-Now-Available-in-the-U-S.html
https://www.fiercepharma.com/marketing/boehringer-partners-cigna-unit-push-biosimilar-humira-after-slow-launch#:~:text=Now%2C%20the%20drugmaker%20has%20unveiled,its%20unbranded%20Humira%20biosimilar%20copy.
https://www.prnewswire.com/news-releases/boehringer-ingelheim-expands-access-to-adalimumab-adbm-injection-the-companys-biosimilar-to-humira-302142539.html
https://www.prnewswire.com/news-releases/celltrion-usas-adalimumab-aaty-biosimilar-to-humira-now-available-at-low-wholesale-acquisition-cost-302141900.html
https://www.reuters.com/business/healthcare-pharmaceuticals/teva-pharm-q1-profit-falls-short-estimates-revenue-gains-2024-05-08/
https://endpts.com/inside-cvs-caremarks-move-that-broke-humiras-hold-on-the-market/
https://www.fiercepharma.com/pharma/sandoz-shows-6-growth-humira-biosimilar-leading-charge
https://endpts.com/boehringer-puts-a-target-on-humira-says-pushing-it-off-formularies-is-necessary/
https://www.pharmaceutical-technology.com/news/fda-boehringer-cyltezo-approval/#:~:text=The%20US%20Food%20and%20Drug,of%20multiple%20chronic%20inflammatory%20diseases.
https://www.prnewswire.com/news-releases/us-fda-approves-high-concentration-citrate-free-formulation-of-cyltezo-adalimumab-adbm-injection-boehringer-ingelheims-interchangeable-biosimilar-to-humira-302132457.html
https://www.globenewswire.com/news-release/2024/04/30/2871900/0/en/U-S-Commercialization-Agreement-with-Quallent-to-Drive-Patient-Savings-with-First-High-Concentration-Citrate-Free-Interchangeable-Biosimilar-to-Humira-adalimumab.html
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-strong-skyrizi-sales-2024-04-26/
https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-offer-humira-rivals-with-0-copay-specialty-pharmacy-2024-04-25/
https://www.fiercepharma.com/pharma/boehringer-ingelheim-leans-late-stage-pipeline-plots-25-new-launches-over-next-decade
https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-lay-off-salespeople-humira-biosimilar-sales-lag-2024-04-04/
https://www.reuters.com/business/healthcare-pharmaceuticals/roivants-anti-inflammatory-drug-succeeds-mid-stage-study-2024-04-02/
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-buy-landos-expand-pipeline-immunity-related-illnesses-2024-03-25/
https://www.fiercepharma.com/pharma/after-long-road-approval-teva-and-alvotech-believe-their-new-humira-biosimilar-simlandi-may
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761299
https://endpts.com/organons-humira-biosimilar-gets-exclusive-spot-on-va-formulary/
https://endpts.com/real-humira-competition-may-not-arrive-until-2026-abbvie-execs-tell-investors/
https://endpts.com/humira-biosimilar-market-remains-stagnant-with-abbvie-losing-only-2-of-market-share-samsung-report-shows/
https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-will-remove-abbvies-humira-some-drug-reimbursement-lists-april-2024-01-03/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154
https://www.fiercepharma.com/pharma/abbvies-humira-takes-back-its-top-spot-icers-annual-list-unsupported-price-hikes
https://endpts.com/abbvie-bets-that-nearly-20b-in-deals-can-bring-it-into-the-post-humira-future/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761219
https://www.globenewswire.com//news-release/2023/11/21/2783692/0/en/Sandoz-launches-Hyrimoz-adalimumab-high-concentration-formulation-in-Europe-aiming-to-improve-patient-care.html
https://endpts.com/fda-approves-an-unbranded-version-of-megablockbuster-humira-but-abbvie-says-it-wont-currently-launch/
https://www.globenewswire.com//news-release/2023/11/07/2775667/0/en/Samsung-Bioepis-Organon-Announce-FDA-Acceptance-of-Supplemental-Biologics-License-Application-sBLA-for-Interchangeability-Designation-for-HADLIMA-adalimumab-bwwd-a-Biosimilar-to-Hu.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125057
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761255
https://endpts.com/abbvies-humira-sales-drop-in-line-with-analyst-projections-and-pharma-takes-imbruvica-impairment-charge/
https://endpts.com/almost-a-year-since-humira-biosimilars-launched-abbvie-still-controls-more-than-97-of-the-us-market/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761118
https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-launches-unbranded-humira-biosimilar-81-discount-2023-10-02/#:~:text=Oct%202%20(Reuters)%20%2D%20Germany's,the%20blockbuster%20rheumatoid%20arthritis%20drug.
https://www.globenewswire.com//news-release/2023/09/20/2746175/0/en/Alvotech-Provides-U-S-Regulatory-Update-on-AVT02-a-High-Concentration-Interchangeable-Biosimilar-Candidate-to-Humira-adalimumab.html
Market Place
Share 
